Netazepide, a specific gastrin antagonist with few if any side effects and proven efficacy in the treatment of gastric NETs, has not been tried in the treatment of gastric cancers although gastrin receptors are frequently expressed. The gene discussed is CCKBR; the disease is gastric cancer.